From news@stockwiz.com  Fri Oct 14 19:52:43 2005
Return-Path: <news@stockwiz.com>
Received: from mx1.FreeBSD.org (mx1.freebsd.org [216.136.204.125])
	by hub.freebsd.org (Postfix) with ESMTP id 8B37B16A41F
	for <bug-followup@freebsd.org>; Fri, 14 Oct 2005 19:52:43 +0000 (GMT)
	(envelope-from news@stockwiz.com)
Received: from CBL217-132-123-166.bb.netvision.net.il (CBL217-132-123-166.bb.netvision.net.il [217.132.123.166])
	by mx1.FreeBSD.org (Postfix) with SMTP id C3B7643D45
	for <bug-followup@freebsd.org>; Fri, 14 Oct 2005 19:52:03 +0000 (GMT)
	(envelope-from news@stockwiz.com)
Received: from unknown (HELO integrating) (192.168.209.62)
    by CBL217-132-123-166.bb.netvision.net.il with SMTP; Fri, 14 Oct 2005 21:51:40 +0200
Message-Id: <5554732810.4028554785@CBL217-132-123-166.bb.netvision.net.il>
Date: Fri, 14 Oct 2005 19:52:03 +0000 (GMT)
From: <news@stockwiz.com>
To: bug-followup@freebsd.org
Subject: Investor Alert

>Number:         87456
>Category:       junk
>Synopsis:       Investor Alert
>Confidential:   no
>Severity:       serious
>Priority:       medium
>Responsible:    gnats-admin
>State:          closed
>Quarter:        
>Keywords:       
>Date-Required:  
>Class:          sw-bug
>Submitter-Id:   current-users
>Arrival-Date:   Fri Oct 14 20:00:24 GMT 2005
>Closed-Date:    Fri Oct 14 20:38:16 GMT 2005
>Last-Modified:  Fri Oct 14 20:38:16 GMT 2005
>Originator:     
>Release:        
>Organization:
>Environment:
>Description:
 Looking for a company with some good news?  Here's one!
 
 Date: 14 Oct 2005
 Company: Worldwide Biotech & Pharmaceutical Group
 Stock: WWBP . OB
 Current Price: $1.80
 Short Term Target: $3
 12month Target: $5 - $7
 
 
 ---
 
 WWBP Receives Positive Response at China Economic Summit 
 for its HCV (Hepatitis C Virus) Technology in Beijing
 
 XI'AN, China, /Xinhua-PRNewswire/ - 
 Worldwide Biotech & Pharmaceutical Group 
 (OTC Bulletin Board: WWBP - News; "WWBP") successfully introduced 
 its Chinese Golden Medal patented invention - 
 "the Intact Hepatitis C Virus (HCV) and Method 
 for Culturing HCV in Vitro by Cell Culture" to conventioneers 
 when Ms Wenxia Guo, CEO and President of WWBP, 
 attended the China Economic Summit held in Beijing.
 
 As a core part of the 8th China Beijing International High-tech Exposition, 
 which is held annually, the China Economic Summit mainly focuses 
 on high-tech innovation and China's sustainable economic growth. 
 Because high-tech innovation was the main theme of the Summit, 
 WWBP seized the opportunity by introducing a leading invention 
 for medical technology named, HCV (Hepatitis C Virus), 
 and more importantly, by this chance WWBP has won an initial success 
 for its recognition and reputation. This Economic Summit has provided 
 WWBP with a platform to introduce its achievement in HVC technology 
 to all the attendants of the Summit across the world.
 
 In fact, China is harboring a third of all chronic hepatitis B (HBV) 
 sufferers and a fourth of chronic hepatitis C (HCV) sufferers, 
 120 million and 41 million people respectively. 
 With this huge potential market, it is clear that the situation 
 WWBP faces is prosperous and but also competitive.
 
 "We are very thankful for being given such a great opportunity 
 to attend the Economic Summit. The theme of this summit 
 which is around innovation let us know that it's the right time 
 for WWBP to quicken the steps ahead to high-end technology development," 
 said Wenxia Guo, CEO and President of WWBP, "WWBP is a biotech company 
 and the technological innovation is our core element. 
 With this predominance, WWBP will quicken the stages 
 of HCV development with all our strength."
 
 
 About Worldwide Biotech & Pharmaceutical (Group) Co., Ltd.
 
 Worldwide Biotech & Pharmaceutical Company ("WWBP") is a hi-tech biotech 
 company with top-ranking pharmaceutical R&D abilities, 
 Good Manufacturing Practices (GMP) licensed manufacturing facilities 
 and a well-established marketing network in China and Southeast Asia. 
 The product range of WWBP covers Hepatitis C Virus (HCV) products, 
 diagnostic medicines and Over-The-Counter (OTC) drugs. 
 WWBP currently possesses of 35,940 square meters of land 
 and 5,359 square meters of GMP standard facilities. 
 With strong pharmaceutical R&D abilities especially in the HCV field, 
 WWBP has been known as the first biotech company in the world 
 to hold the technology of culturing intact HCV in vitro by cell culture. 
 Its principle project "the Intact Hepatitis C Virus (HCV) and Method 
 for Culturing HCV in Vitro by Cell Culture" was awarded 
 with a Chinese patent by the China Patent Bureau 
 and the prestigious China Patent Golden Medal 
 by the World Intellectual Property Organization and China Patent Bureau. 
 The medal is the only one issued for achievement 
 in the biomedical sciences during the past 10 years. 
 WWBP has achieved a GMP production scale level of 10,000 ml 
 for concentrated HCV material and 10 grams HCV antigen per month, 
 which is expected to bring WWBP considerable gross sale revenue 
 each year and greatly strengthen the company's R&D 
 on anti-HCV drug screen and HCV human vaccine. 
 WWBP has successfully reached two merger agreements 
 with pharmaceutical companies in China, all of which have scalable production 
 and well-established sales network and the acquiring is expected 
 to be finished before the end of August 2005. 
 The acquisitions will strengthen WWBP's R&D abilities 
 and production scale, as well as extend its marketing network 
 throughout China and Southeast Asia. WWBP has been working closely 
 with pharmaceutical research institutes, and has established connections 
 with both central & local governments.
 
 
 About the China Economic Summit
 
 The China Economic Summit was held at the Great Hall of the People 
 in Beijing on May 24, 2005 and, it is a main part 
 of the 8th China Beijing International High-tech Exposition. 
 This summit will focus on the following key items: "2005 China Innovation Year", 
 "Financial Innovation", "Enterprise Governing and China's Economic 
 Sustainable Growth." During the summit, a number of famous economists 
 and entrepreneurs gave a brilliant debate on key areas. 
 
 
 About HCV (Hepatitis C Virus) Technology
 
 HCV is a small, enveloped, single-stranded, blood-borne RNA virus 
 in the family Flaviviridae. HCV is a major cause of liver disease 
 in the United States and the world. WWBP has committed a large amount 
 of cash and resources to the development of its cornerstone technology: 
 a laboratory method for culturing (growing, propagating) 
 intact Hepatitis C Virus. After three years of intensive research, 
 the scientists at WWBP achieved a technological breakthrough 
 for culturing HCV in vitro, making it the first to overcome 
 the main hurdle to HCV research and product development. 
 The breakthrough in establishing a cell culture system for HCV production 
 and infection by WWBP scientists provides a potentially unlimited source 
 for HCV and a comprehensive technology platform upon which the Company 
 can be built. From this Rosetta stone, WWBP hopes to development 
 new generation HCV diagnostics, new classes of HCV drugs, HCV vaccines 
 and to be part of the development of next-generation anti-HCV targeted 
 (gene) therapies.
 
 ---
 
 ..Whatever you do WATCH WWBP...
 WE GIVE IT TO YOU AGAIN AS A GIFT. THIS COMPANY IS DOING INCREDIBLE THINGS.
 THAY HAVE CASH AND HAVE MADE GREAT STRATEGIC AQUISITIONS. CURRENT PRICE $1.80
 WORD ON THE SREET IS THIS COULD TAKE OFF AT ANY MOMENT AND DOUBLE. THIS COMPANY
 HAS DROPPED BIG NEW'S IN THE PAST. WHO'S TO SAY THEY DON'T HAVE ANOTHER BIG ONE.
 
 
 
>How-To-Repeat:
>Fix:
>Release-Note:
>Audit-Trail:
State-Changed-From-To: open->closed 
State-Changed-By: linimon 
State-Changed-When: Fri Oct 14 20:37:58 GMT 2005 
State-Changed-Why:  
GNATS does not speculate. 

http://www.freebsd.org/cgi/query-pr.cgi?pr=87456 
>Unformatted:
